PROCEPT BioRobotics Corpo... (PRCT)
PROCEPT BioRobotics Corporation (PRCT) Stock Price, Analysis & Data
No hay datos disponibles
| Precio de compra | n/a |
| Capitalización de mercado | 1.23B |
| Ingresos (TTM) | 337.34M |
| Beneficio neto (TTM) | -109.75M |
| Beta | 0.89 |
| EPS (TTM) | -1.95 |
| Ratio PER (TTM) | n/a |
| Adelante PE | -18.78 |
| P/B (TTM) | 3.64 |
| P/S (TTM) | 3.68 |
| Earnings Date | Nov 4, 2026 |
| Precio de venta | n/a |
| Volumen | 750,330 |
| Volumen medio (20D) | 1,680,153 |
| Abierto | 22.10 |
| Anterior Cerrar | 21.95 |
| Rango del día | 21.40 - 22.10 |
| Rango de 52 semanas | 16.66 - 42.70 |
| analista | n/a |
| Precio objetivo | n/a |
| Dividendos | n/a |
| Fecha ex dividendo | n/a |
Acerca de PRCT
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided rob...
Desempeño financiero
En 2025, los ingresos de PROCEPT BioRobotics fueron 308.05M, un aumento de 37.22% en comparación con 224.5M del año anterior. Las ganancias fueron -95.57M, un aumento de 4.55%.
Estados financierosSorpresa de resultados
Los analistas proyectan ingresos de ... Actualizar
1 semana hace · Simply Wall St.
PROCEPT BioRobotics (PRCT) Stock Sees Fair Value Falls As Analysts Cut Growth ViewsPrice targets for PROCEPT BioRobotics have been reset closer to its revised fair value, with many now clustered in the low to mid US$20s instead of around US$30. Analysts linking these lower targets t...
